{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:27:42Z","timestamp":1776410862021,"version":"3.51.2"},"reference-count":39,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15492","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:15:13Z","timestamp":1771244113000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Penile metastasis from prostate cancer with CDK12 mutation:\u00a0A case report and literature review"],"prefix":"10.3892","volume":"31","author":[{"given":"Qi","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Urology, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510900, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanwu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiwen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"key20260417093312_b1-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"593","DOI":"10.5114\/jcb.2021.109754","article-title":"Brachytherapy for oligometastatic prostate cancer to the penis","volume":"13","author":"Martz","year":"2021","journal-title":"J Contemp Brachytherapy"},{"key":"key20260417093312_b2-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.radcr.2016.04.003","article-title":"Relevance of computed tomography and magnetic resonance imaging for penile metastasis after prostatectomy: uncommon case report and brief review of the literature","volume":"11","author":"Fiaschetti","year":"2016","journal-title":"Radiol Case Rep"},{"key":"key20260417093312_b3-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"1395301","DOI":"10.3389\/fonc.2024.1395301","article-title":"Case report: Malignant priapism: Penile metastasis from prostate cancer with low serum PSA level","volume":"14","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"key":"key20260417093312_b4-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"key20260417093312_b5-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"189247","DOI":"10.1016\/j.bbcan.2024.189247","article-title":"Roles of CDK12 mutations in PCa development and treatment","volume":"1880","author":"Jiang","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"key20260417093312_b6-ol-31-4-15492","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20260417093312_b7-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.eururo.2016.03.011","article-title":"Pathology and genetics: Tumours of the urinary system and male genital system: clinical implications of the 4th Edition of the WHO Classification and Beyond","volume":"70","author":"Montironi","year":"2016","journal-title":"Eur Urol"},{"key":"key20260417093312_b8-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/ijnm.IJNM_107_17","article-title":"Penile metastasis from prostate cancer presenting as malignant priapism detected using gallium-68 prostate-specific membrane antigen positron emission tomography\/computed tomography","volume":"33","author":"Kamaleshwaran","year":"2018","journal-title":"Indian J Nucl Med"},{"key":"key20260417093312_b9-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.radcr.2021.02.064","article-title":"Patient with penile metastasis from prostate cancer and survival over 5 years: A case report with longitudinal evaluation using computed tomography and magnetic resonance imaging","volume":"16","author":"Fujita","year":"2021","journal-title":"Radiol Case Rep"},{"key":"key20260417093312_b10-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.18632\/oncotarget.23366","article-title":"Prognosis of men with penile metastasis and malignant priapism: A systematic review","volume":"9","author":"Cocci","year":"2017","journal-title":"Oncotarget"},{"key":"key20260417093312_b11-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.2164\/jandrol.112.016873","article-title":"Priapism as the initial manifestation of a penile and lower limb cutaneous metastasis of prostate adenocarcinoma with low serum PSA level","volume":"33","author":"He","year":"2012","journal-title":"J Androl"},{"key":"key20260417093312_b12-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0090-4295(02)02431-7","article-title":"Penile metastasis of chondrosarcoma of the jaw","volume":"61","author":"Cardoso Guimar\u00e3es","year":"2003","journal-title":"Urology"},{"key":"key20260417093312_b13-ol-31-4-15492","first-page":"90","article-title":"Malignant Priapism Secondary to Metastatic Prostate Cancer: A case report and review of literature","volume":"13","author":"Lin","year":"2011","journal-title":"Rev Urol"},{"key":"key20260417093312_b14-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"qfac011","DOI":"10.1093\/sexmed\/qfac011","article-title":"Penile metastasis from prostate cancer misdiagnosed as Peyronie disease: A case report","volume":"11","author":"Dai","year":"2023","journal-title":"Sex Med"},{"key":"key20260417093312_b15-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.diii.2012.01.020","article-title":"Imaging tumours of the penis","volume":"93","author":"Rocher","year":"2012","journal-title":"Diagn Interv Imaging"},{"key":"key20260417093312_b16-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/1754-9485.13052","article-title":"Prostate penile metastasis: Incidence and imaging pattern on 68 Ga-PSMA PET\/CT","volume":"64","author":"Tatkovic","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"key":"key20260417093312_b17-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4103\/ijnm.ijnm_123_22","article-title":"Solitary penile metastasis from prostate cancer on 18F-Prostate-specific membrane antigen positron emission tomography\/computed tomography","volume":"37","author":"Dhull","year":"2022","journal-title":"Indian J Nucl Med"},{"key":"key20260417093312_b18-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/CU9.0000000000000093","article-title":"Penile metastasis in prostate cancer patients: Two case reports, surgical excision technique, and literature review","volume":"17","author":"Landen","year":"2023","journal-title":"Curr Urol"},{"key":"key20260417093312_b19-ol-31-4-15492","first-page":"2985","article-title":"Response to cabazitaxel beyond 20 cycles in a patient with penile metastasis of prostate cancer: A case report","volume":"14","author":"Atag","year":"2017","journal-title":"Urol J"},{"key":"key20260417093312_b20-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/00000658-194206000-00030","article-title":"Effect of orchiectomy and irradiation on cancer of the prostate","volume":"115","author":"Huggins","year":"1942","journal-title":"Ann Surg"},{"key":"key20260417093312_b21-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.2019.37.7_suppl.687","article-title":"ARCHES: A Randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20260417093312_b22-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"key20260417093312_b23-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"key20260417093312_b24-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"key":"key20260417093312_b25-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): Final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"key20260417093312_b26-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"key20260417093312_b27-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"key20260417093312_b28-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"key20260417093312_b29-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: Extended analysis of the phase 3 PREVAIL Study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"key20260417093312_b30-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/21541264.2018.1535211","article-title":"Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium","volume":"10","author":"Greenleaf","year":"2019","journal-title":"Transcription"},{"key":"key20260417093312_b31-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14737140.2023.2168647","article-title":"Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: A meta-analysis","volume":"23","author":"Zhang","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20260417093312_b32-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.eururo.2020.03.024","article-title":"Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics","volume":"78","author":"Nguyen","year":"2020","journal-title":"Eur Urol"},{"key":"key20260417093312_b33-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"905","DOI":"10.6004\/jnccn.2020.7663","article-title":"Use of circulating tumor DNA for the clinical management of metastatic castration-resistant prostate cancer: A multicenter, real-world study","volume":"19","author":"Dong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260417093312_b34-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.eururo.2019.09.036","article-title":"Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer","volume":"77","author":"Reimers","year":"2020","journal-title":"Eur Urol"},{"key":"key20260417093312_b35-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/PO.19.00383","article-title":"CDK12-mutated prostate cancer: Clinical outcomes with standard therapies and immune checkpoint blockade","volume":"4","author":"Schweizer","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"key20260417093312_b36-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2147\/OTT.S377638","article-title":"Chronological liquid biopsy reveals the impact of platinum-based chemotherapy on a prostate cancer patient's CDK12 mutation: A case report","volume":"15","author":"Zhu","year":"2022","journal-title":"Onco Targets Ther"},{"key":"key20260417093312_b37-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"e1421","DOI":"10.1634\/theoncologist.2020-0260","article-title":"Long-term disease control using taxane\/platinum-based chemotherapy in CDK12-mutated advanced prostate cancer","volume":"25","author":"Barata","year":"2020","journal-title":"Oncologist"},{"key":"key20260417093312_b38-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/iju5.12824","article-title":"A case of testicular dysgenesis syndrome with squamous cell carcinoma of the prostate harboring a CDK12 mutation","volume":"8","author":"Murata","year":"2025","journal-title":"IJU Case Rep"},{"key":"key20260417093312_b39-ol-31-4-15492","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1200\/PO.19.00346","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations","volume":"4","author":"Mota","year":"2020","journal-title":"JCO Precis Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:33:21Z","timestamp":1776407601000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,16]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15492","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}